Clinical Trials List
2014-07-15 - 2021-03-30
Phase III
Recruiting5
ICD-10C61
Malignant neoplasm of prostate
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9185
Malignant neoplasm of prostate
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/19
Investigators and Locations
Co-Principal Investigator
- Yeong-Shiau Pu Division of Urology
- 戴槐青 Division of Urology
- SHUO-MENG WANG Division of Urology
- - - Division of Urology
- Yu-Chieh Tsai Division of Urology
- - - Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shian-Shiang Wang Division of Urology
- 熊小澐 Division of Urology
- Chuan-Shu Chen Division of Urology
- 林萬鈺 Division of Urology
- Cheng-Kuang Yang Division of Urology
- Jian-Ri Li Division of Urology
- 洪啟峰 Division of Urology
- Cheng-Che Chen Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 余家政 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Tsung-Yi Huang Division of Urology
- Hung-Lung Ke Division of Urology
- Hsiang Ying Lee Division of Urology
- 黃俊農 Division of Urology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張英勛 Division of Hematology & Oncology
- 劉忠一 Division of Urology
- Rita cheng Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
1500 participants
